Navigation Links
China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
Date:5/18/2009

GANSU, China, May 18 /PRNewswire-Asia-FirstCall/ -- China Dasheng Biotechnology Company ("China Dasheng" or "the Company") (OTC Bulletin Board: CDBT), a leading producer and distributor of organic bacteria based additives for crops and livestock feeds in the PRC, announced unaudited financial results for the third quarter of fiscal year 2009, which ended March 31, 2009.

    Highlights for Q3 FY2009 (all figures in US$) included:

    -- Total revenue grew approximately 43% to $5.3 million in the third
       quarter of 2009, compared with $3.7 million in the prior year quarter;
    -- Gross margin improved by 50% to $2.6 million in the third quarter of
       2009, compared with $1.8 million in the prior year quarter;
    -- Operating expenses, as a percentage of revenue, were reduced by over
       900 basis points to 20.2% in the third quarter of 2009, compared to
       29.9% in the prior year quarter;
    -- Income from operations increased by 140% to $1.6 million in the third
       quarter of 2009, compared to $0.7 million in the prior year quarter;
    -- Net income rose over 200% to $1.3 million in the third quarter of 2009,
       or $0.04 per diluted share, compared with $0.4 million, or $0.01 per
       share in the prior year quarter;
    -- $10.4 million of cash on the balance sheet as of the quarter end, March
       31, 2009.

Chairman of the Board, Mr. Jinjun Qi commented, "China Dasheng reported another successful quarter, demonstrating the power and continued strength of our core business offerings. There is a growing demand in China at both the national and local level for "going Green" agriculture and the Company is uniquely position to capitalize on this trend with our proprietary products and leading market position.

During the third quarter we posted solid year-over-year revenue growth all while continuing to deliver sustained and growing cash flows, enabling us
'/>"/>

SOURCE China Dasheng Biotechnology Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... , Nov. 24, 2014  Spherix Incorporated (Nasdaq: ... committed to the fostering and monetization of intellectual ... VTech Telecommunications Ltd.,  Case No. 3:13-cv-03494-M and  Spherix ... 3:13-cv-03496-M, both in the United States District Court ... . On November 21, ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... The “Chiral Chromatography Columns Market by ... Glass, Plastic), by Application [GC, LC (HPLC, UHPLC, ... 2018” analyses and studies the major market drivers, ... Asia, and Rest of the World. , Browse ... through 135 pages and in-depth TOC on “Chiral ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2CannLabs Secures $750,000 Line Of Credit 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... Inc. (Nasdaq: NVAX ) today announced that it ... press release to be issued after 8:00 a.m. Eastern Time ... investor conference call to discuss its financial results at 10:00 ... will be hosted by Novavax President and Chief Executive Officer ...
... May 4 The Arcas Group, a ... Stefan Terwindt, MBA as Executive Vice President. He will ... Terwindt previously served as President of Imedex, Inc."Stefan is ... and skills to our company," said Founder and President ...
... & Company, LLC, a Boston-based life science investment bank, ... has joined the firm as senior advisor. In ... on internal and client-related activities including private equity placements ... focus on medical device transactions. "We are thrilled ...
Cached Biology Technology:Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call 2The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/2/2014)... In this month,s issue of Physics World , ... bridging the "valley of death" to take their innovations ... argues that the gruelling challenge facing all start-up companies ... harder for physicists because of two main factors: physics-based ... and they often turn out to be a lot ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... developed at the Hebrew University of Jerusalem that is ... led to approval by the U.S. Food and Drug ... cardiac surgery patients. The product is the ... biodegradable polymers for the prevention of post-surgical adhesions. SyntheMed ...
... available in German . , Helsinki/Leipzig. ... trading, will only be successful if they are coherently ... issues, says a report published today by the Partnership ... from seven of the biggest European environmental research institutes. ...
... Both plant and human diseases that can travel ... more rapidly than has been understood, according to a ... only for some human diseases but also a new ... done by scientists at Oregon State University and other ...
Cached Biology News:Hebrew University professor's work leads to FDA approval for product 2Climate change aims need to be better integrated 2New wheat disease could spread faster than expected 2New wheat disease could spread faster than expected 3